Home/Sathgen Therapeutics/Sangeeta Srivastava
SS

Sangeeta Srivastava

Executive Director

Sathgen Therapeutics

Therapeutic Areas

Sathgen Therapeutics Pipeline

DrugIndicationPhase
MSP008-22Triple‑negative breast cancer and other solid tumorsPhase 1
SBGBLMultiple solid tumors (TNBC, prostate, oral, glioblastoma, hepatic, cervical, colon, lung)Preclinical
LSPGBLMultiple solid tumors (TNBC, prostate, oral, glioblastoma, hepatic, cervical, colon, lung)Preclinical
METGBLVarious solid tumors (tyrosine kinase driven)Preclinical